Debra Dobson Email and Phone Number
M&A strategy executive experienced in both Private Equity and Fortune 200 (Danaher Corp: DHR) firms with proven ability to frame complex ideas, provide clarity in market dynamics, identify key drivers to build conviction for both inorganic and organic growth initiatives. Accomplished senior leader skilled as both a strategist and in high impact operating roles who routinely partners with C-level executives to challenge the status quo, driving performance in global businesses across multiple disciplines, regions and functions. Excels in corporate development, strategic development and general management roles with aggressive growth mandates. Twenty years of industry experience primarily in Life Sciences, Health Care & Clinical Diagnostics, Medical Devices, Technology / B2B Software and Financial Services / Private Equity.Specialties: Mergers and Acquisitions; Global Strategic Planning and Execution; General Management; Market Research, Analysis and Business Development; Global Business Performance Management; Partnering and Joint Ventures; Business Integrations, Carve-outs and Change Management
-
PartnerPeloton Capital Management Feb 2020 - PresentToronto, Ontario, CaPrimary focus areas: Transaction sourcing and execution in healthcare & other target sectors, investment team development and mentoring and leading PCM's value creation capabilities. For value creation, responsible for the on-going development of a suite of tools, processes and techniques to help PCM’s portfolio companies reach their full potential.Board member for portfolio companies: Glass Lewis and The Fertility Partners
-
Vice President, Business Development - Product Id PlatformDanaher Corporation Nov 2017 - Feb 2020- Responsible for defining, championing and executing on the inorganic growth strategy for the platform focused on consumer goods & pharma product realization. (>$2.0B combined revenue, 5 core businesses)- Identify the strategic growth vectors, leads the build out of market work, the M&A funnel, target company cultivation, diligence, and deal execution. - Latest acquisition completed was in July 2018 of Blue Software, an attractive bolt-on, which expanded Esko’s leading position in its Brand Owner software business.
-
Corporate Director, Strategic DevelopmentDanaher Corporation Dec 2015 - Nov 2017- Developed a proprietary market framework, led funnel review process with a monthly market/target review cadence for new vertical market entry (M&A targets >$1B)- Led annual company-wide Danaher strategic planning process introducing a new strategic planning workstream focused on execution, workshops, core modules to the curriculum and a refresh of the portal - Led China strategy workshop for executives with >$1.5B combined revenue in China and scaled this workshop to India- Transaction: Generated insights into microbiology and the runway for molecular diagnostics contributing to the buy investment thesis of Cepheid ($4B)
-
Global Director, Strategic Planning & Corporate DevelopmentSciex Mar 2013 - Nov 2015Framingham, Ma, UsA $750 M global analytical technologies business, part of Danaher Corporation's Life Sciences platform, focused on mass spectrometry solutions for academic, pharma/biotech, clinical, food & environmental labs- Owner of the annual strategic planning process with growth priorities range from expanding integrated solutions, changing business models through informatics/web, entering adjacent markets & enhancing commercial capabilities in high growth regions. Result: Achieved above market growth over past 3 years.- Lead rigorous external market analyses to understand key competitor and customer dynamics for the synthesis of vital business issues, insights and profiling of adjacent growth opportunities for M&A activity.- Led the transaction, integration and creation of a new Separations business unit (~$130 M global revenue) achieving value creation performance targets (revenue & opex synergies), a broadened technology offering and expansion of global commercial operations (sales, marketing & service). -
Director, Tripletof Product Management & Accurate Mass BusinessSciex May 2011 - Feb 2013Framingham, Ma, Us- Global management of our flagship business (>$75M) with focus on meeting revenue, margin and customer satisfaction targets - driving the marketing strategy, product roadmap and development process.- Led new product release teams, market analysis, competitive response, sales training and strategic planning for the accurate mass business.- Identify and develop collaborations and relationships with leading third party solution providers to extend the commercial value of the accurate mass product portfolioAchievements: - Exceeded global full-year plan and forecast revenue targets in FY 2011 & 2012. - Executed the first global product launch outside of North America (Beijing, China – May 2012) - Extended portfolio through two prioritized and compressed development cycles by gaining cross-functional team alignment & funding.
-
Director, Strategy & Corporate DevelopmentSciex 2008 - 2011Framingham, Ma, Us- Project manager for the divestiture of MDS Analytical Technologies business to Danaher Corp ($1.1 B transaction involving 4 publicly traded companies) including management presentations and interviews, extensive due diligence, legal agreement review and negotiation cycles- Product portfolio evaluation of the businesses at the gross margin and operating margin level to support growth, investment and divestment priorities- Transactions: Divestiture and carve-out of Perkin Elmer joint venture mass spectrometry business from SCIEX and Acquisition and carve-in of microplate reader business from Beckman Coulter
-
Director, Financial Planning & AnalysisMds Analytical Technologies Jun 2006 - Sep 2008King Of Prussia, Pennsylvania, Us- Responsible for the management reporting, financial reporting, business planning, forecasting, cost accounting and analytical activities with a team of 5 Finance professionals - Enhanced this function by translating financial results to business impact through understanding and educating of key business drivers and performance indicators- Integrated the Molecular Devices ($250M Rev) business into the planning, reporting and performance management cycles. Lead the integration team in identifying, realizing and reporting synergy targets. -
Manager, 4000 Value Stream ManufacturingMds Analytical Technologies Sep 2005 - Sep 2006King Of Prussia, Pennsylvania, Us- Production manager with 45 direct reports of primary product family (API 4000 based instruments) from procurement to performance test to delivery of systems - Facilitated the transfer of this product line to Singapore - Achieved consistent delivery on production commitments while driving productivity improvements which included a 25% reduction in overtime
-
General Manager, Executive Health ClinicsMds Jun 2004 - Jul 2005King Of Prussia, Pennsylvania, Us- General management with business scope of two geographic sites, 15 staff, 14 physician consultants, 4 practice consultants and 5 main service lines- Leadership responsibilities include financial management (P&L, pricing, budget & capex), performance management and management of sales and marketing, administrative, and clinical operations- Succeeded in evaluating, stabilizing and turning around the performance of the clinics – creating go-forward options- Successfully led, negotiated and closed the sale of MDS’ Executive Clinics to a strategic buyer- Performance improvements included: Increased revenue by 15% on a year-over-year basis, Increased operating margin by 19% on a year-over-year basis, Staffing: Re-defined roles, key hires and top-grading
-
AssociateEdgestone Capital Partners Jun 2001 - Aug 2002Toronto, Ontario, Ca- Investment professional at a private equity firm with over $1 billion capital under management.- Supported all the funds (late-stage equity, mezzanine and venture capital) in evaluating target industries and investment opportunities, negotiating transactions, conducting due diligence, screening senior management, coordinating external advisors and providing guidance to portfolio companies- Led a team in raising $30 M of capital for an investment pool in 4 months that involved administering the fund, marketing and direct sales to over 200 potential investors
Debra Dobson Education Details
-
University Of TorontoGeneral -
University Of TorontoFinancial Engineering
-
Queen'S UniversityMechanical Engineering
-
Queen'S UniversityMechanical Engineering
Frequently Asked Questions about Debra Dobson
What company does Debra Dobson work for?
Debra Dobson works for Peloton Capital Management
What is Debra Dobson's role at the current company?
Debra Dobson's current role is Partner at Peloton Capital Management.
What schools did Debra Dobson attend?
Debra Dobson attended University Of Toronto, University Of Toronto, Queen's University, Queen's University.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial